Kornimate/medical-research-clean huggingface dataset:
digital strategies to advance help-seeking aim 1 and 2

Conditions: Clinical High Risk; Early Psychosis; First Episode Psychosis

Summary: this proposal aims to establish a digital laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at clinical high-risk (chr) for developing psychosis. leveraging the health action process approach (hapa) model, this study will identify help-seeking subtypes in 25,000 youth who screen positive for psychosis-risk on mental health america's national online screening platform, iteratively develop and test theory and data-driven, personalized strategies to advance help-seeking using micro-randomized trials and a sequential multiple assignment randomized trial, identify the most accurate chr screening threshold in an online environment, and link youth, when indicated, to local clinical care via accelerating medicines partnership - schizophrenia (amp-scz), a nih funded national network of chr programs throughout the us. this academic-industry partnership aims to curate one of the largest datasets of youth with chr, and to develop effective strategies to enhance early help-seeking, in a population where help-seeking is critical and a significant barrier to care.

aim 1: characterize help-seeking patterns in 25,000 youth who score above prodromal-questionnaire (pq-b) threshold. h1a: youth will cluster into (1) pre-intenders (take the pq-b and engage with educational content), (2) intenders (initiate a text exchange with a strong365 peer navigator (3) actors (advance from texting to clinical assessment with a strong365 clinician over phone/video) and (4) super-actors (advance from assessment to amp-scz intake). data will include online metadata (time spent online, # of resources viewed, time spent to complete the pq-b, # of texts initiated/exchanged), self-report (demographics, symptom type and severity, pq-b score, goals/needs, self-efficacy), and natural language. h1b (strong365 only): natural language processing (nlp) of data extracted from participant/provider interactions over text and video will identify linguistic markers of hapa stages: intender, actor, super-actor. models based on hapa stages, along with behavioral features (i.e., message timing, frequency, response lag) will predict help-seeking advancement vs. disengagement. top predictive features will be used to inform the crafting of help-seeking advancement strategies to be tested in mrts (aim 3). aim 2: to ensure that those who complete the pq-b are directed appropriately, this study will establish the most accurate threshold for identifying chr online. h2: using data from population-based pq-b screening, the investigators predict that a total distress score of 20+ will generate the highest diagnostic odds ratio with a sensitivity of at least 80% online, as determined by remote clinical assessment. for the remainder of the study, the threshold score that maximizes specificity and sensitivity will be used.

Eligibility criteria:
inclusion criteria: * ages 12-29 years * living within a 50-mile radius of a us based amp-scz site * able to complete the english language pq-b on mha's screening platform
evaluation of effectiveness and safety of ultimaster™ tansei™ stent in routine clinical practice

Conditions: Coronary Artery Disease

Summary: this study is to evaluate the effectiveness and safety of ultimaster tansei stent in the "real-world" daily practice.


Eligibility criteria:
inclusion criteria: 1. patients ≥ 19 years old 2. patients receiving ultimaster™ tansei™ stents. 3. the patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate institutional review board/ethics committee of the respective clinical site. exclusion criteria: 1. patients with a mixture of other drug-eluting stents (dess) 2. terminal illness with life-expectancy ≤1 year. 3. patients with cardiogenic shock

Keywords: tansei ultimaster ultimaster tansei
physiotherapy in the reduction of post-needling soreness

Conditions: Dry Needling; Soreness, Muscle; Trigger Point Pain, Myofascial

Summary: dry needling is a minimally invasive technique which generates good results and neuromuscular benefits. its application involves a highly prevalent effect called post-needling soreness. it is defined as a residual pain, located in the incision area, with a self-limiting period of 24-72 hours, as a result of a physiological process generated by the technique. so far, different clinical trials have been carried out to measure the effectiveness of several techniques for reducing post-needling soreness, reaching positive results. however, no studies have been found with the aim of distinguish which method is more effective for this goal; therefore, it is clear the need to continue investigating on the subject and comparing these techniques among them.

main objective. to figure out if one of the four techniques (isometric, concentric, eccentric contraction exercise and analytic passive stretching) is more effective for reducing post- needling soreness immediately, at 12, 24, 48 and 72 hours. objectives. to verify if there is a correlation between independent variables and post-needling soreness. study type. non-blinded randomized clinical trial. intervention. dry needling on an active myofascial trigger point in superior trapezius, followed by one of the following treatments according to the specific group: 1) concentric contraction exercise, 2) isometric contraction exercise, 3) eccentric contraction exercise or 4) analytic passive stretching.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years; * cervical pain. * presence of an active pgm in the upper trapezius muscle. exclusion criteria: * traumatic history in the cervical region; * inability to understand or perform the required exercises; * pregnancy in the first trimester; * altered state of coagulation; * immunosuppression status; * state of alteration of sensitivity (e.g. central sensitization processes, fibromyalgia, etc.); * unavoidable fear of needles; * lack of knowledge about the use of the whatsapp or telegram messaging platform
intranasal glutathione in parkinson's disease

Conditions: Parkinson's Disease (PD)

Summary: excessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of parkinson's disease (pd) pathophysiology. while there is rationale for the therapeutic use of reduced glutathione (gsh) in pd, and even some preliminary evidence to suggest the use of gsh can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility of this therapy. intranasal gsh, (in)gsh, is a novel method of delivery for this popular cam therapy in patients with pd, and bypasses the obstacles associated with other delivery methods. it has been used in clinical practice since 2005. the aim of this study is to evaluate safety, tolerability, and preliminary absorption data of (in)gsh in volunteers with pd in a phase i single ascending dose escalation study.

individuals will be randomized to one of three treatment (100 mg gsh/ ml, 200 mg gsh/ ml, or placebo) arms in a double-blind fashion. all study medication will be administered 1 ml three times daily for three months, with a one-month wash out.

Eligibility criteria:
inclusion criteria: 1. diagnosis of parkinson's disease made by neurologist within previous 10 years 2. modified hoehn and yahr stage \<3 3. age \>20 4. subjects must be able to attend study visits at screening, baseline, weeks 4, 8, 12, 16 5. subjects must be able to demonstrate self-administration of study medication or have active caregiver who can administer daily. 6. dose and frequency of all pharmaceutical medications must be stable for one month prior to enrollment. 7. diet, exercise and supplementation must be kept constant throughout participation in study 8. ability to read and speak english exclusion criteria: 1. dementia as evidenced by montreal cognitive assessment (moca) \<24 2. diseases with features common to parkinson's disease (eg. essential tremor, multiple system atrophy, progressive supranuclear palsy) 3. epilepsy 4. history of stroke, cva 5. elevated levels of alt, ast, bun or creatinine 6. chronic sinusitis as defined by snot-20 score \>1.0 on items 1-10. 7. presence of other serious illness 8. history of brain surgery 9. history of structural brain damage 10. history of intranasal telangiectasia 11. supplementation with glutathione and agents shown to increase glutathione will not be permitted and will require a 90 day washout period. 12. pregnant or at risk of becoming pregnant.

Keywords: parkinson's disease neuroprotection glutathione intranasal
prognostic biomarkers in predicting mortality in respiratory patients with ventilator-associated pneumonia

Conditions: Ventilator Associated Pneumonia

Summary: the aim of this study is to evaluate prognostic efficiency rdw and nlr for mortality prediction in respiratory patients with vap.

ventilator-associated pneumonia (vap) is the most common nosocomial infection. vap continues to be a leading cause of morbidity and mortality in the nosocomial setting. red cell distribution width (rdw) and neutrophil-lymphocyte ratio (nlr) are prognostic factors to mortality in different diseases.

Eligibility criteria:
inclusion criteria: * respiratory failure needs mechanical ventilator support \> 48 hrs. vap was defined as an acute lower respiratory tract infection in mechanically ventilated patient \> 48 hrs with a new or progressing infiltrate on chest radiograph and who met at least two of the following clinical criteria: body temperature \>38°c or \ 10,000 /mm3 or \<5000 /mm3, or a macroscopically purulent tracheal aspirate * only the first vap episode was included exclusion criteria: * neutropenia (\< 500 cells/ml) before the development of vap. * conditions are known to influence total and differential wbc counts such as chronic inflammatory conditions, hematologic disorders, history of chemotherapy, or radiotherapy within 4 weeks before enrollment. * conditions are known to affect rdw as anemia due to nutritional deficiency (ie, iron, vitamin b12, and folic acid). * patients with hiv/aids

Keywords: red cell distribution width neutrophil-lymphocyte ratio intensive care units respiratory
study of nk combined with chemotherapy for advanced solid tumor

Conditions: Solid Tumor

Summary: combinations natural killer cell (nk) with chemotherapy treatment may enhance the immune response and stop cancer cells from growing.

patients in group a will receive 4 cycles of nk treatments within 8 months. patients in group b will have no immunotherapy. chemotherapy are available in both groups.the investigators want to evaluate the efficacy of combination of nk with chemotherapy in patients with treatment-refractory solid tumors

Eligibility criteria:
inclusion criteria: 1. patients with treatment-refractory advanced solid cancer can not accept operation; 2. age 10 to 90 years; 3. eastern cooperative oncology group (ecog) score ≤ 2 points; 4. estimate survival \> 3 months; 5. blood white blood cell(wbc)≥ 4×109/l, hb ≥ 100g/l, platelet count (plt)≥ 80×109/l; alanine amino transferase (alt) and aspartate amino transferase (ast)≤ 2 times of normal upper value; serum cr ≤ 2 normal upper value; 6. without any other malignant disease; 7. with more than one scalable lesions; 8. patients voluntary attempt, and informed consent; 9. women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus. exclusion criteria: 1. patients who do not conform to the inclusion criteria; 2. patients with uncontrolled infection; underlying disease that was severe or life-threatening (such as uncontrolled brain metastasis ); 3. patients who were pregnant or lactating; 4. ecog perform status ≥ 2;4. 5. other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.)
effect of lymphedema prevention program based on theory of knowledge-attitude-practice on postoperative breast cancer patients

Conditions: Breast Cancer Lymphedema

Summary: according to the inclusion and exclusion criteria, a total of 108 patients were enrolled and randomly divided into control group (n = 56) and intervention group (n = 52). the control group received routine nursing, while the intervention group received upper limb lymphedema prevention program for breast cancer patients after surgery. before surgery, at the third chemotherapy (about 2.1 months after surgery) and the sixth chemotherapy (about 4.2 months after surgery), the self-designed general information questionnaire was used to investigate the patient's basic situation, and the corresponding tools were used to measure the volume of the patient's upper arm, the grip strength of the affected arm, and the range of motion of the affected shoulder joint.


Eligibility criteria:
inclusion criteria: * female patients were≥18 years old * pathological puncture confirmed breast cancer with unilateral, no recurrence, and no metastasis * patients with clinical tnm stageⅰ\~ⅲ * patients with proposed surgery and 6 or more chemotherapy * the patient was conscious and aware of his condition, with no cognitive impairment or communication problems exclusion criteria: * patients who had cancer other than breast cancer * patients who had history of arm or neck trauma, infection or surgery * patients who had serious diseases such as cardiovascular, cerebrovascular, liver, kidney, etc * patients who had upper limb disability or the affected limb has edema before surgery * patients who had thrombus in the blood vessels of the affected limb
etanercept treating patient with acute st segment elevated myocardial infarction

Conditions: Myocardial Infarction

Summary: our aim is to observe whether anti-tnf-alpha regimen will effect serum adiponectin concentration after myocardial infarction/reperfusion and also beneficial for the patients undergoing percutaneous coronary intervention (pci).

ischemic/reperfusion injury in patients with acute myocardial infarction (ami) undergoing percutaneous coronary intervention (pci) is associated with increased inflammatory cytokines that including tnf-alpha that can exert deleterious effects and therefore contribute to cardiac dysfunction and cardiomyocytes apoptosis. several studies on rodents have reported administration of stnfr-fc, a scavenger of the pro-inflammatory cytokine tnf-alpha at the time of reperfusion would protect against ischemic/reperfusion injury. also reports had shown that serum tnf-alpha concentration is negatively correlated with a cardioprotective cytokine adiponectin. adiponectin (ad) is an abundant protein hormone regulatory of numerous metabolic processes. the major intracellular pathway activated by ad includes phosphorylation of amp-activated protein kinase, which is responsible for many of ad's metabolic regulatory, anti-inflammatory, vascular protective, and anti-ischemic properties. the aim of the present study was to verify whether the administration of etanercept, an fda approved rheumatoid arthritis treating stnfr-fc, at the reperfusion time would protect against ischemic/reperfusion injury on patient, and effect serum adiponectin level.

Eligibility criteria:
inclusion criteria: * patients with acute st segment elevated myocardial infarction in 12h exclusion criteria: * cardiogenic shock * old myocardial infarction * other causes of cardiac insufficiency * tumor * coronary anatomy unsuitable for pci or need of emergency coronary artery by-pass grafting * pregnancy

Keywords: etanercept acute st segment elevated myocardial infarction percutaneous coronary intervention myocardial reperfusion injury
maintenance therapy: lenalidomide following bendamustine and rituximab induction therapy for chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: this study will determine whether or not lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).


Eligibility criteria:
inclusion criteria: * previous induction treatment with bendamustine and rituximab * 18 or more years of age * chronic lymphocytic leukemia * ecog performance status less than or equal to 2 * absolute neutrophile count more than 1,000 * platelet count more than 70,000 exclusion criteria: * serious medical condition that would prevent treatment with lenalidomide * evidence of tumor lysis syndrome * any prior treatment with lenalidomide

Keywords: chronic lymphocytic leukemia maintenance therapy
new 3d printed wrist orthosis

Conditions: Carpal Tunnel Syndrome; Ulnar Nerve Injury; Rhizarthrosis; Tendinopathy, Thumb; Tenosynovitis de Quervain; Hand Disease

Summary: in order to offer a new product improving the healing and/or rehabilitation of injuries or injuries to the wrist and hand, médicus is seeking to develop a new orthosis for the wrist and hand by 3d printing. this project will focus on the development of an orthosis related to carpal tunnel syndrome as well as droopy hand. among the issues to be addressed in this development proposal, the investigators find: 1) identification of the best methodology for taking digital impressions; design of an orthosis with the following characteristics: (i) no external attachment system, (ii) spiral design with a thumb ring, (iii) manufacturing by 3d printing and (iv) a cost of less than $150 ;3) performing technical and clinical trials.


Eligibility criteria:
inclusion criteria: * be between 18 and 70 years old * ability to accurately communicate comfort and discomfort, * carpal tunnel syndrome, or * de quervain's tenosynovitis, or * drop hand, or * ulnar nerve damage * rhizarthrosis, or * tendinopathy of the thumb * and/or ulnar gale exclusion criteria: * - spasticity in the upper limbs * paralysis, insensitivity of the upper limbs * neuromuscular pathology affecting the upper limbs
use of serum m2bp and msus to predict arthritis in psoriatic patients

Conditions: Psoriasis

Summary: aims of the study: 1. measurement of serum level of mac 2 binding protein among patients with psoriasis, psoriatic arthritis and subclinical psoriatic arthritis compared with healthy individuals. 2. evaluation of msus findings in patients with psa and subclinical psoriatic arthritis 3. evaluation of the role of serum level of mac 2 binding protein and msus in predicting arthritis among psoriatic patients.

psoriasis is a quite common chronic, inflammatory immune-mediated skin disease affecting about 2% of the population . also psoriasis is a strong risk factor for the development of several comorbidities of which the most common is psoriatic arthritis (psa). the presence of cutaneous psoriasis indicates a high risk for developing psa. studies conducted in dermatology clinics have shown a high prevalence of undiagnosed psa in psoriasis patients , therefore identifying soluble biomarkers for psa in psoriasis patients may help in early diagnosis, and thereby prevent disability and improve quality of life . mac 2 binding protein \[m2bp\] is thought to be a marker of synovial cell activation and joint destruction .m2bp may be involved in the pathogenesis of psa . recently, with the introduction of new medications and wider use of musculoskeletal ultrasound (us) imaging in clinical practice, the possibility of earlier us diagnosis in patients with psoriasis in the pre-clinical phase of psa has been examined.

Eligibility criteria:
inclusion criteria: cutaneous psoriasis psoriatic arthritis subclunical psoriatic arthritis exclusion criteria: any history of liver diseases non-alcoholic fatty liver, viral hepatitis, human immunodeficiency virus (hiv), autoimmune rheumatic disease other than psoriasis and psa malignancy.
effect of transversus thoracic muscle plane block (ttmp) on analgesia

Conditions: Coronary Artery Bypass; Anesthesia, Conduction; Nerve Block; Pain, Postoperative

Summary: in this prospective and controlled study, the investigators investigated the effect of transversus thoracic muscle plane block (ttmp) on analgesia in patients who undergo coronary artery bypass graft (cabg) surgery with median sternotomy. for this purpose, the investigators aimed to compare the hemodynamic responses to surgical incision and sternotomy and, pain intensity, total analgesic consumption, additional analgesic requirements of the patients in the first 24 hours after extubation under postoperative patient-controlled analgesia (pca) adminisration.

forty-six patients aged 18-70 years, asa class i-iii, who undergo cabg surgery were included in our study. the patients were randomized into the ttkpb group and the control group. heart rate (hr) and mean arterial pressure (map) were recorded before peroperative induction, before skin incision, after skin incision, before sternotomy and after sternotomy. pca with tramadol was applied after extubation and "numeric rating scale" nrs scores, total tramadol consumption, number of requests and additional analgesic requirements were recorded at 0, 1, 2, 4, 8, 12 and 24 hours.

Eligibility criteria:
inclusion criteria: * asa (american society of anesthesiologists) classification i-iii * coronary artery bypass graft operation with median sternotomy under elective conditions exclusion criteria: * refusing to participate in the study * under 18 and over 70 * asa class iv and above * ef (ejection fraction) \< 40% * emergency surgery or reoperation * intraaortic balloon pump placement * known allergy to local anesthetics * coagulation disorder * infection at the block site * history of sternotomy * those with chronic pain complaints and long-term use of analgesics * patients who could not be extubated within 12 hours after the operation

Keywords: transversus thoracic muscle plane block, postopertive pain, sternotomy